• Explore /
  • Poster
  • / Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.

Abstract Poster

Authors

null

Ciara Conduit

Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, Australia

Ciara Conduit , Ganessan Kichenadasse , Carole A. Harris , Howard Gurney , Tom Ferguson , Francis Parnis , Jeffrey C. Goh , Michelle Frances Morris , Craig Underhill , David William Pook , Ian D. Davis , Felicia Roncolato , Michelle L. Harrison , Stephen Begbie , Anthony M. Joshua , Emma Link , Elizabeth J. Hovey , Craig Gedye

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03177239

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4537)

DOI

10.1200/JCO.2022.40.16_suppl.4537

Abstract #

4537

Poster Bd #

28

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).

UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).

First Author: Craig Gedye

First Author: Craig Gedye

First Author: Lorenzo Pilla

First Author: Michael B. Atkins